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Abstract
Background: Government policy encourages increasing involvement of patients in their long-term care. This paper
describes the development and pilot evaluation of a ‘Medication Review Tool’ designed to assist people to participate
more effectively in discussions about antipsychotic drug treatment.
Methods: The Medication Review Tool developed consisted of a form to help patients identify pros and cons of their
current antipsychotic treatment and any desired changes. It was associated with a website containing information and
links about antipsychotics. For the trial, participants diagnosed with psychotic disorders were recruited from community
mental health services. Cluster randomisation was used to allocate health professionals (care co-ordinators) and their
associated patients to use of the Medication Review Tool or usual care. All participants had a medical consultation
scheduled, and those in the intervention group completed the Medication Review Tool, with the help of their health
professional prior to this, and took the completed Form into the consultation. Two follow-up interviews were conducted
up to three months after the consultation. The principal outcome was the Decision Self Efficacy Scale (DSES). Qualitative
feedback was collected from patients in the intervention group.
Results: One hundred and thirty patients were screened, sixty patients were randomised, 51 completed the first
follow-up assessment and 49 completed the second. Many patients were not randomised due to the timing of
their consultation, and involvement of health professionals was inconsistent. There was no difference between
the groups on the DSES (-4.16 95 % CI -9.81, 1.49), symptoms, side effects, antipsychotic doses or patient
satisfaction. Scores on the Medication Adherence Questionnaire indicated an increase in participants’ reported
inclination to adherence in the intervention group (coefficient adjusted for baseline values -0.44; 95 % CI -0.76,
-0.11), and there was a small increase in positive attitudes to antipsychotic medication (Drug Attitude Inventory,
adjusted coefficient 1.65; 95 % CI -0.09, 3.40). Qualitative feedback indicated patients valued the Tool for
identifying both positive and negative aspects of drug treatment.
Conclusions: The trial demonstrated the design was feasible, although challenges included service re-configurations
and maintaining health professional involvement. Results may indicate a more intensive and sustained intervention is
required to facilitate participation in decision-making for this group of patients.
Trial registration: Current controlled trials ISRCTN12055530, Retrospectively registered 9/12/2013.
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Background
Providing more patient-centred care and facilitating self-
management of medical treatment in long-term condi-
tions is at the heart of the health agenda in the United
Kingdom [1], along with much of the rest of the world.
The “recovery movement” in mental health also aims to
empower patients to build more fulfilling lives by exer-
cising more control over their conditions and treatment
[2, 3]. Following this agenda, many areas of medicine
have introduced measures to help involve patients more
closely in decisions about their treatment. A Cochrane
review of trials of shared decision-making interventions
indicated they could increase knowledge, increase confi-
dence in decisions and facilitate more active patient
involvement [4].
The importance of involving patients with mental
health problems more closely in decisions about using
psychiatric medication was highlighted by research
which found high levels of non-adherence and extensive
prescribing that exceeded recommended dose limits for
antipsychotic drugs [5]. In response to these findings the
United Kingdom government recommended that a more
systematic consideration of the pros and cons of taking
medication is needed and that patients should be more
involved in medication reviews [6].
Antipsychotics effectively reduce acute psychotic
symptoms and continuing use can prevent relapse [7, 8].
However, they are associated with a range of physical
complications and are reported to be subjectively un-
pleasant to take [9, 10]. Hence levels of non-adherence
are high [11]. Balancing the benefits of treatment against
its potential negative effects is a complex task. If patients
fail to appreciate the benefits of treatment and stop taking
medication, they risk deterioration, relapse and hospital-
isation [8]. On the other hand, patients report being more
troubled by the adverse physical and mental effects of
drug treatment than professionals commonly recognise
[12] and these can significantly impair patients’ quality of
life [13]. Reducing prescribed doses where possible may
therefore improve adherence and reduce the personal and
social costs associated with psychiatric morbidity, as well
as those directly related to the physical complications of
antipsychotics. One study found that 47 % of inpatients
with schizophrenia were dissatisfied with decisions about
medication, and this was more likely if they did not feel
they had been involved in the decision [14].
National Institute for Health and Care Excellence
(NICE) guidelines on the treatment of schizophrenia
emphasise the importance of doctors and patients mak-
ing collaborative decisions about drug treatment, based
on “informed discussion” [15]. There has been little
research on decision making in mental health, however,
although people with schizophrenia and depression do
express a desire to be more involved in decisions about
their treatment [16, 17]. Some shared decision-making
programmes for people with depression and schizophre-
nia indicated benefits in terms of knowledge levels,
patient participation, satisfaction, improved adherence
and symptoms [18–20]. However, the programmes for
people with schizophrenia were conducted intensively with
inpatients, and may prove difficult to translate into routine
community mental health work. A recent internet-based
decision aid aimed at people with schizophrenia in the
community did not affect perceived involvement in
decision-making [21]. Another community based interven-
tion, using electronic care-planning to facilitate shared
decision-making, improved satisfaction among health pro-
fessionals (case managers) but not patients [22]. A recent
systematic review of a diverse collection of eleven trials
with a shared decision-making component, found a small
impact on various measures of ‘empowerment’ (including
measures of patient involvement and perceived efficacy in
decision-making), and a trend towards reduced occurrence
of future compulsory treatment. There was no overall ef-
fect on decision-making ability or quality of the therapeutic
relationship [23].
Aims and hypotheses
Many people attending community mental health services
take antipsychotic drugs, often for long periods. The
current research aimed to help patients assess and com-
municate more effectively about the personal risks and
benefits that taking antipsychotic medication involves. By
improving patient participation in the decision making
process, we aimed to improve satisfaction with prescribed
medication and clinical outcomes. We also aimed to
improve prescribing practice, by focusing on patients’
main concerns, and encouraging the adjustment of anti-
psychotic doses where appropriate.
To facilitate these aims the first part of the research
involved the development of a Medication Review Tool.
The tool was designed for routine use in community
mental health services, so we did not adopt the inten-
sive methods of some previous shared decision making
programmes. The Tool was intended to help patients
systematically evaluate the pros and cons of their
current antipsychotic medication, and to share their
views with their psychiatrists. It was developed using
insights from a qualitative study and refined and
piloted in consultation with patients, carers and profes-
sionals. A pilot randomised controlled trial was then
conducted to evaluate the use of the Medication
Review Tool in community mental health services. The
principal hypothesis was that use of the Tool would
improve patients’ ability to participate effectively in
decisions about their antipsychotic medication as
measured by the Decision Self Efficacy Scale [24].
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Methods
Intervention development
An initial draft of the Medication Review Tool was
designed by the study management group, using insights
from the literature on Decision Aids in general medicine.
The Tool was modelled initially on the Ottowa Personal
Decision Guide, and customised to address issues specific
to antipsychotic medication [25]. It was designed to be
accessible to both patients and professionals, to be
implemented in routine practice, and to enable patients to
consider all aspects of their antipsychotic treatment.
Feedback on the first draft of the Tool was gathered dur-
ing a qualitative interview study involving 20 participants
with a diagnosis of schizophrenia, psychosis or schizoaf-
fective disorder, who were taking antipsychotic medication
(described fully elsewhere).
Following the study, a website was constructed, and a
revised draft of the tool was incorporated into the
website. Feedback on the website and the new draft of
the Medication Review Tool was obtained through two
group feedback sessions with patients (four participants
each) and one with carers (five participants), and
further individual consultation with two patients, one
carer and two professionals.
The Medication Review Tool and website were
finalised after the consultation. The website was de-
signed to provide information about psychotic condi-
tions including schizophrenia, types of antipsychotic
medication and points for people to consider when
discussing and making decisions about medication with
professionals. It included links to external sites for users
to access more detailed information. The Medication
Review Tool, which was downloadable from the website,
consists of a one page form, designed in an accessible
format to allow patients to list the principal benefits and
disadvantages of antipsychotic medication that they
experience, changes they would like to be considered and
other points for discussion. It is intended to be filled in by
the patient, with support from a professional if necessary,
and then taken into a psychiatric consultation about
medication to enable them to express their views about
medication more clearly and to have their concerns
addressed more systematically. The website was password
protected for the duration of the study to prevent
contamination between groups during the pilot trial.
Pilot trial
Participants
The study aimed to recruit a total of sixty (n = 60)
participants from Community Recovery teams, which
include patients with established mental health problems
who need ongoing support, and Early Intervention in
Psychosis Services, which cater for patients up to age 35
with a recent onset of psychotic illness. The study took
place at the North East London Foundation Trust
(NELFT) which covers a large section of outer London
including economically deprived and more affluent areas.
Participants had to be over the age of 18, have a diagnosis
of psychosis, schizophrenia, schizoaffective disorder,
delusional disorder or a mood disorder with psychotic
symptoms and be currently taking antipsychotic medica-
tion. Participants were required to have an allocated health
professional (care-coordinator or case manager), who was
usually a nurse, social worker or occupational therapist
from the participant’s clinical team. They also needed to
have a consultation with their psychiatrist pending within
the next three months, usually a Care Programme
Approach meeting involving the psychiatrist (Patients on
the ‘Care Programme Approach’ are assessed as having
complex needs, have an allocated care-coordinator who
acts as a keyworker and also coordinates all aspects of care,
and are required to have regular multi-disciplinary reviews,
which would normally involve a team psychiatrist).
Individuals who could not speak English or lacked
capacity to consent were excluded from the study. The
trial was approved by the Camden and Islington Research
Ethics Committee, London (12/LO/0959).
Procedures
Health professionals who were willing to participate in
the study were asked to approach potential participants
from their caseload. The health professional then intro-
duced the study and obtained verbal consent for the
research team to contact the patient. Patients who
agreed were sent an information sheet through the post,
followed up by a telephone call by a member of the
research team to provide more information and address
any queries. If the patient agreed, a member of the
research team then met with them to request informed
consent and carry out the baseline interview.
When all the potential study recruits associated with a
particular health professional had completed their base-
line assessments, the health professional was randomly
allocated either to use the Medication Review Tool with
participants, or to provide ‘treatment as usual’ (Fig. 1).
Health professionals were intended to be involved in
helping patients engage with the intervention due to
chronicity of symptoms and high levels of functional
impairment in the study population. Health professionals
allocated to the intervention group were provided with
15 minute training session on how to help patients use
the Medication Review Tool. Training consisted of
explaining the rationale of the study, introducing health
professionals to the website and the Form, illustrating
how they could help participants access further informa-
tion and consider a range of medication-related issues,
and demonstrating how they would complete the Form
with participants.
Moncrieff et al. BMC Psychiatry  (2016) 16:205 Page 3 of 11
Thus the study was a cluster randomised trial with
health professionals as the unit of randomisation. It was
not possible to blind patients or health professionals due
to the nature of the intervention, and data collection
was not blinded due to the fact there was only one prin-
cipal researcher assigned to the study. Statistical analyses
were conducted blind, however (see below).
Cluster randomisation was carried out using an internet
based randomisation service (Sealed Envelope) using
blocks of size 4, 6 and 8. The allocation list was held by an
independent administrator from Priment clinical trials unit
at University College London in order to achieve conceal-
ment of allocation. Following randomisation, participants
in the intervention group were sent a link to the website
along with the login details (username and password).
Individuals who did not have access to the internet were
sent printed hard copies of the information on the website.
The website details or information was sent to the partici-
pant a few weeks before the pre-booked consultation so
that they could have the opportunity to look through the
website and the form in their own time if they chose to do
so prior to looking at it with their health professional.
Participants then met with their key health profes-
sionals or care-coordinators to look at the website and
complete the form. This meeting was intended to take
place about a week before the consultation. When
clients had completed the form, a copy was placed in
their electronic clinical records, and they were given the
hard copy to keep and take to the meeting. Consultations
with psychiatrists normally involve a review of the patient’s
medication and the completed form was intended to be
shared with the psychiatrist during the meeting in order to
contribute to this process.
Outcome assessment
Follow-up was conducted in two stages. There was an
initial telephone or face to face interview conducted 2 to
4 weeks after the participant’s consultation meeting. This
interview focused on feedback and measures of the
nature of the consultation. The second follow-up inter-
view took place face to face two to three months after
the consultation, and focused on symptoms, side effects
and adherence (Fig. 1).
The primary outcome measure was the Decision Self-
Efficacy Scale (DSES), an 11-item questionnaire used to
assess participants’ confidence in participating in clinical
discussions and decisions [24]. Each item has five possible
responses, which are scored 0 (not at all confident), to 4
(very confident). These scores are summed giving a total
score between 0 and 44, with higher scores indicating
higher decision self-efficacy. This measure has been val-
idated in people with schizophrenia [26]. Participants
completed the questionnaire at baseline and at the first
follow-up.
Secondary outcomes included total scores on the
Client Satisfaction Questionnaire (CSQ-8) [27], collected
at first follow-up, and the Drug Attitude Inventory 10
(DAI-10) [28], the Liverpool University Neuroleptic
Side Effect Rating Scale (LUNSERS) [29] and the Brief
Positive and Negative Syndrome Scale (Brief PANSS),
all collected at second follow-up. The Brief PANSS
was developed by Yamamoto et al 2010 and correlates
highly with the full PANSS [30]. We added an item on
hallucinations, since this is not included, and it was
anticipated to be a common symptom among our sample.
At second follow-up the Medication Adherence Question-
naire [31] was also completed, and an item from the
Fig. 1 Study design
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Tablets Routine Questionnaire [32] on doses of medica-
tion missed during the preceding week. Participants were
also asked about any changes to their antipsychotic and
other medications since the baseline interview, and these
data were checked against medical records, with the
participant’s permission. Daily doses of antipsychotics in
chlorpromazine equivalents were calculated at baseline
and follow-up, and the number of different antipsychotic
drugs patients were taking was also recorded.
Feedback on the implementation of the intervention, and
qualitative data concerning participants’ views on the
process of using the Medication Review Tool was collected
using a short semi-structured interview at the first follow-
up point with participants allocated to this group. This in-
cluded questions about the practicalities of using the tool
and website, how the tool had been employed during the
consultation, and whether the participant had found the
process helpful or not. Responses were either audio-
recorded or recorded in note form by the interviewer.
Data analysis
Quantitative data was entered into the Statistical Package
for the Social Sciences (SPSS) [33], and then transferred
into Stata version 13 for statistical analysis [34]. Demo-
graphics and baseline variables were described. A formal
sample size calculation was not carried out due to the
study being a pilot, but we aimed to recruit 60 service
users. This number was thought to be more than adequate
to assess trial processes and obtain outcome data with
which to perform future sample size estimation.
Continuous and dichotomous outcomes were analysed
using random effects modelling, to account for cluster-
ing by care coordinator. All models included only the
baseline value of the outcome (where appropriate) and
the randomised group. This is because of the relatively
small sample size not supporting further variables in the
model and the decreased likelihood of the model conver-
ging with more variables included.
Process outcomes included recruitment rate, dropout
rate and number (percentage) of completers. These are
reported using the Consolidated Standards of Reporting
Trials (CONSORT) diagram (Fig. 2). The intraclass
correlation coefficient was calculated for the primary
outcome (DSES) using the health professional as the
cluster. All statistical analyses were conducted by the
study statistician who remained blind to allocation until
all the results were agreed.
Qualitative feedback data were analysed using a
theoretically-oriented form of thematic analysis [35], that
focused on two issues: descriptions of how the Medication
Review Tool had been implemented, and experiences of
the impact of using the tool. Both commonalities and
variations in respondents’ accounts of implementation
process and the interventions’ impact were explored.
Results
Process outcomes
The CONSORT diagram for the trial is presented in
Fig. 2. Sixty participants were recruited over a period of
11 months. Thirty-one participants were randomised to
the intervention group and 29 to the treatment as usual
group. A total of 54 potential participants (26 %) out of
the 207 individuals referred for the study were not able
to be included in the study because it was not possible
to organise a baseline assessment prior to the clinical
consultation. Thirty one individuals were ineligible (in
most cases due to not having a diagnosis of a psychotic
disorder), 49 declined participation and 12 were not
included for other reasons such as the participant or
care-coordinator not responding to contact requests.
The cluster design required that all the patients assigned
to a particular health professional had to have baseline
interviews before the care-coordinator could be rando-
mised. Delays in organising baseline interviews for some
participants meant pre-scheduled psychiatric consulta-
tions came and went before they were randomised. In
order to keep participants who had already had baseline
assessments in the study therefore, sometimes a decision
had to be taken to randomise health professionals before
all their potential patients had had the opportunity to
have a baseline interview. Reasons for delay in organis-
ing baseline assessments included difficulty in contacting
participants, participants moving house, being admitted
to hospital, or having other less severe deteriorations of
mental state, and delay in health professionals contacting
patients to make the initial introduction to the research.
Twenty seven of those randomised to the intervention
group completed the intervention. Implementing the
Medication Review Tool intervention was also difficult
partly due to service reconfigurations that occurred during
the course of the study, which meant there were frequent
changes to participants’ allocated health professionals.
Some health professionals also found it difficult to find
time to do the training or complete the form with clients,
and in five cases the research assistant performed this task
instead due to care-coordinators being ill or unavailable
for other reasons.
Rates of follow-up were good, with 85 % of patients
completing the first follow-up, and 81 % the final follow-
up. Qualitative data was obtained from 22 patients in
the intervention group.
Participant characteristics
Demographic characteristics and baseline values of out-
come measures are displayed in Table 1. Those in the
intervention group were on average six years older than
those in the intervention group and a greater percentage
were single, unemployed and white. Antipsychotic use was
comparable between groups, as was other medication;
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though a greater percentage in the treatment as usual
group were taking anticholinergic drugs and drugs re-
ferred to as ‘mood stabilisers’. Baseline values for outcome
measures were similar between groups (Table 2).
Efficacy
Table 2 shows the baseline and follow-up values of the
measures used, with comparisons between groups ad-
justed for baseline values where possible. Contrary to
the study hypothesis, the Decision Self Efficacy Scale
scores were lower in the Medication Review Tool group
than in the Treatment as usual group after adjustment
for baseline score -4.16 (95 % CI -9.81, 1.49). Scores on
the Medication Adherence Questionnaire indicated a
statistically significant difference with patients in the
intervention group indicating a greater tendency to be
adherent with medication compared to those in the
treatment as usual group. The Medication Adherence
Questionnaire consists of four questions about partici-
pants’ inclination to adhere to medication, such as
whether they ever forget to take medication, or are
sometimes careless about taking it [31]. Higher scores
indicate less inclination to adherence. Attitudes towards
antipsychotic treatment as measured by the Drug
Attitude Inventory [28] were also more favourable in the
intervention group (higher scores indicate better subject-
ive response to medication) (Table 2).
There were no differences in brief PANSS scores, side
effects, doses of antipsychotics at follow-up in chlorpro-
mazine equivalents, use of two or more antipsychotics
or in client satisfaction at follow-up (Table 2).
More patients in the intervention group had changes
in their antipsychotic medication. Nine had an increase
in dose as measured by total chlorpromazine equiva-
lents, and eight had a decrease (N = 25). In the treat-
ment as usual group six had an increase, and four had
Fig. 2 Recruitment flowchart (CONSORT diagram)
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a decrease (N = 24). Overall, however, there was no dif-
ference between the groups in terms of the change in
the chlorpromazine equivalent dose of antipsychotics
(Table 2).
The intraclass correlation coefficient (ICC) for the
primary outcome, the DSES, for clusters greater than
one, was 0.07 (95 % CI 0.00, 0.46).
Implementation feedback
Six of the 22 respondents reported completing the
Medication Review Tool with the care-coordinator as
planned, but nine reported that they had completed it
on their own, and two said they did it with the
psychiatrist during their consultation. Three could not
remember completing the Tool (although they had
done so) and two did not provide any information on
this. Respondents reported spending between two
minutes and 30 min considering and completing the
Medication Review Tool, the median time being
10 min (based on data from 18 respondents). Fifteen
of the 22 respondents recalled showing the Tool or
form to their psychiatrist during the consultation, or
in one case discussed the contents of the form during
the consultation, but completed it afterwards. Two
respondents had not shown the Tool to their psych-
iatrist, and were not certain if the psychiatrist had
seen a completed copy or not. One of these respon-
dents was disappointed; the other was not concerned
since there had been a satisfactory discussion of
medication during the consultation in any case.
When asked about their use of the supporting
information, six respondents had read the printout of
the information on the website which had been sent to
them. Only one had looked at the website itself, how-
ever. Nine had looked at neither and five did not supply
any information. Three of those who looked at the infor-
mation on the website or in printed form described it as
helpful, three said it was not helpful, and one did not
express an opinion.
Impact of using the medication review tool
Most respondents reported finding the Medication
Review Tool helpful to some degree (N = 13). Reasons
given were that completing the Medication Review Tool
helped to clarify the benefits of antipsychotic medica-
tion, or the reasons why someone might be taking it,
and in some cases its side effects.
Two participants suggested it had resulted in a more
positive attitude towards medication:
‘It made me understand why I am taking what I am
taking’ (P 27).
Table 1 Baseline characteristics
Variable Treatment as usual Medication review tool
n/N or mean % or (SD) n/N or mean % or (SD)
Male 20/29 69 23/31 74
Age 39 (11) 45 (10)
White 21/29 72 25/31 81
Single 20/29 69 25/31 81
Unemployed 20/29 69 24/31 77
Number of years been in contact
with mental health services
Less than a year 1/29 3 1/31 3
1 to 3 years 3/29 10 4/31 13
4–10 years 5/29 17 2/31 6
More than 10 years 20/29 69 24/31 77
One antipsychotic 22/29 76 27/31 87
Two antipsychotics or more 7/29 24 4/31 13
Total dose per day (Chlorpromazine
equivalent (mg)) median (IQR)
400 200, 600 250 132, 400
Taking other medication 24/29 83 23/31 74
Antidepressants 9/29 31 10/31 32
Anxiolytic 2/29 7 3/31 10
Anti cholinergic 10/29 34 7/31 23
Mood stabilisers 9/29 31 5/31 16
Medication for physical illnesses 17/29 59 18/31 58
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‘I was able to identify what was good about the
medication that I hadn’t done before. I always
used to think about the negatives. It made me
feel better about the medication doing some
good’ (P 44).
Four participants suggested that completing the form
had made them aware of the full extent of the side
effects they experienced.
[completing the Tool] ‘made me think about all the
side-effects of the medication and realise that, you
know, I needed to push forward about getting
something done about it’ (P 33).
Five participants felt that completing the form had
influenced the way clinical staff viewed their medica-
tion, and in some cases had led to adjustments in
doses of medication during the medication review
meeting:
‘it made her [the psychiatrist] see all the side effects
and what they do’ (P 19).
One participant was disappointed that the psychiatrist
had not taken any notice of the form and its contents,
and two others felt it had made no difference to their
own views about medication, or to the outcome of their
consultation.
Two participants said they had no interest in the
process and had not found it helpful. One of these
described how completing the Medication Review
Tool had made him anxious, because he became gen-
erally anxious when having to complete forms.
Discussion
Process outcomes
The study showed that it was possible to introduce a
Medication Review Tool designed to improve patients’
ability to participate in discussions and decisions about
their antipsychotic medication into routine clinical
services. The pilot trial demonstrated that patients could
be recruited, randomised and most retained for follow-
up at three months. The intervention was not always
implemented as planned, however, and the involvement
of health professionals (care-coordinators) was inconsist-
ent. Feedback illustrated that most participants did not
access information on the internet, and were more likely
to read printed information. The fact that the website
was password protected might have acted as a deterrent
to some participants.
Efficacy results
Although this was not a fully powered trial, the results
did not suggest that the use of a Medication Review
Tool for patients with psychotic disorders and schizo-
phrenia increased participants’ confidence in making de-
cisions about their antipsychotic treatment. It may have
increased the inclination towards medication adherence
and produced marginally more positive attitudes towards
antipsychotic medication. Given the small sample size
these findings could be false positives, but alternatively
they may indicate that providing patients with the
opportunity to reflect on their treatment made them
more aware of its positive effects. This was supported by
qualitative data from some patients, although others
suggested that the process highlighted the negative
aspects of medication. In contrast, a German study of
shared decision-making training for people with
Table 2 Analysis of outcomes
Treatment as usual Medication review tool Coefficient or OR (95 % CI)
Baseline Follow-up Baseline Follow-up
Outcome
Decision Self Efficacy Scale (mean, SD) 29 (9) 32 (10) 29 (10) 30 (9) -4.16 (-9.81, 1.49)
Drug Attitude Inventory (mean, SD) 5 (4) 3 (4) 5 (4) 5 (3) 1.65 (-0.09, 3.40)
LUNSERS (mean, SD) 38 (23) 28 (19) 38 (23) 30 (20) -0.42 (-8.12, 7.29)
Brief PANSS (mean, SD) 18 (7) 16 (7) 17 (7) 16 (6) 0.13 (-2.21, 2.48)
Client Satisfaction Questionnaire (mean, SD) 28 (5) 27 (5) -0.29 (-3.04, 2.45)a
Medication Adherence Questionnaire (median, IQR) 0 (0, 1) 1 (0, 1) 0 (0, 0) 0 (0, 1) -0.44 (-0.76, -0.11)
2 or more antipsychotics taken (n/N, %) 7/29 (24) 7/24 (29) 4/31 (13) 7/26 (27) 0.89 (0.26, 3.08)b
Dose (chlorpromazine equivalents) (median, IQR) 400 (200, 600) 350 (200, 648) 250 (132, 400) 292 (200, 462) -26.02 (-97.23, 45.20)
Change in chlorpromazine equivalent baseline-FU
(median, IQR)
0 (0, 50) 0 (-64, 65) 3.33 (-78.12, 84.79)
Abbreviations: SD standard deviation, LUNSERS Liverpool University neuroleptic side effect rating scale, PANSS positive and negative syndrome scale,
IQR interquartile range, FU follow-up, OR odds ratio
aThere is no baseline adjustment for this analysis
bOdds ratio. Data were too sparse to do the adjusted analysis
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schizophrenia found that patients who underwent
training became more sceptical about medication [20].
Another possibility is that use of the Tool could lead
to dose reduction which might enhance positive atti-
tudes to medication by reducing side effects. However,
there was no evidence that dose reduction had occurred
more commonly among the intervention group in this
study. Alternatively, the present finding may reflect a
Hawthorne-type effect, whereby the process of using the
Medication Review Tool made participants more inclined
to make positive statements about medication to gain the
interviewer’s approval.
The intervention did not affect symptoms of schizo-
phrenia, side effects or dosages of antipsychotics. The
qualitative feedback indicated that some patients found
using the Medication Review Tool helped them clarify
benefits and side effects of antipsychotic medication,
and to think about what changes, if any, they would like
to be made to their medication in the future. Several pa-
tients felt that using the form had influenced clinical
staff and given them more understanding of the patient’s
experience of taking these particular drugs. Others, how-
ever, had little interest in considering their medication in
more detail, and some forgot they had used the instru-
ment at all.
Limitations
The design of the study was challenging in several ways.
Firstly, although cluster randomisation helps prevent
contamination, the current design meant many willing
and eligible patients could not be included, because of
the need to complete baseline interviews on all the pa-
tients allocated to a health professional prior to random-
isation. This problem was greatly exacerbated by service
re-configurations and changes to staff that took place
during the course of the study. Individual randomisation
may have been easier to implement, but would have
risked contamination either through participants com-
paring treatment or by care coordinators introducing
the intervention, or elements of it, to participants in the
treatment as usual group. Cluster randomisation by
team would have avoided the problem of contamination,
but requires larger sample sizes, and would probably
have taken longer to recruit all potential participants
from a team before randomisation could take place. A
non-randomised cohort study comparing outcomes of
patients under the care of teams in which the Medica-
tion Review Tool was introduced with patients from
other, comparable teams would have been easier to im-
plement, but would have had lower credibility than a
randomised trial, since there are likely to be differences
between groups due to geographical location, demo-
graphics and illness profile.
Secondly, the participation of health professionals was
inconsistent, due to competing demands on their time.
The present study was aimed at enhancing patients’
ability to communicate their wishes about medication,
but the lack of attention paid to psychiatrists, and their
part in discussing treatment options, may have limited
the implementation and efficacy of the intervention.
Thirdly, the study population may have found it diffi-
cult to engage with a short and simple intervention such
as the one developed. Although some participants
reported finding the Medication Review Tool useful,
others did not, and some had even forgotten using it.
This may reflect the extent to which some people with
long histories of mental illness come to feel disempow-
ered and disengaged, perhaps through a combination of
the nature of their condition and experiences of services.
A one-off intervention, such as the one investigated
here, may be insufficient to improve patient involvement
in decision-making for this population. A recent trial of
an internet-based shared decision making programme
for community patients with psychotic disorders in the
Netherlands also found that it failed to produce the
anticipated improvements in participation in decision-
making. Moreover, only a third of patients in the
intervention group accessed the web-based decision aid
that was provided to them [21]. A cross-diagnostic
electronic shared-decision making intervention evaluated
in community mental health services in the United States
also failed to improve patient satisfaction, although it did
increase patient recall of their care plans [22].
Other limitations include the fact that the trial was
only conducted with English-speaking patients, which
restricts its generalisability to non-English speaking pop-
ulations, who are likely to have particular difficulties
with communicating views about their treatment.
Implications for further research
Qualitative work would be useful to explore the obsta-
cles to further involvement of patients with long-term
mental illness in decisions about their treatment. For
people who have been involved with services for many
years, more intensive, repeated interventions, such as
those trialled in inpatient settings, may be required
[19, 20]. Education aimed at professionals, teams and ser-
vices may also be necessary to instil a culture in which
more active patient involvement is accepted as worth
promoting. A design using whole teams as clusters
could be more effective than the current design, with
a sustained and repeated intervention integrated into
team working practices, and education and training
conducted at a team level. Further involvement of
psychiatrists in the process of enhancing decision
making could also improve levels of patient participa-
tion. Psychiatrists were not directly involved in
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administering the current intervention, and including
training for psychiatrists to facilitate patient involve-
ment might improve chances of success.
Conclusions
The study set out to develop a tool to help patients
become more involved in making decisions about the
use of antipsychotic medication and to test this tool in a
pilot trial. The trial was implemented successfully, but
process data pointed to difficulties arising from timing
pressures, staff motivation and service reconfigurations.
Although not powered to provide definitive data, the
results did not suggest that the tool had the intended
impact in patients’ confidence in decisions about their
medication. It may have had a small effect on attitudes
towards adherence and to antipsychotic medication
generally, although these may be chance findings, given
the small numbers. In qualitative feedback, patients
identified the benefits of using an instrument that
allowed them to focus on the positive and negative as-
pects of antipsychotic treatment, and to communicate
their experiences to clinical staff. The research may
reflect the ongoing difficulties of introducing new prior-
ities, and the challenges that still lie ahead for efforts to
empower long-term users of mental health services.
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